Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/10/2022* -- Results Q3 2022 -- 0.72 --
11/10/2022* 08:00 EST Earnings Call Q3 2022 -- -- --
08/04/2022 -- Results Q2 2022 0.79 0.78 1.36%
08/04/2022 08:00 EST Earnings Call Q2 2022 -- -- --
05/05/2022 -- Results Q1 2022 0.60 0.72 -15.94%
05/05/2022 08:00 EST Earnings Call Q1 2022 -- -- --
02/15/2022 -- Results Q4 2021 0.80 0.78 3.69%
02/15/2022 08:00 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 11/10/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/04/2022
Beat/Miss Upgrade
Return Since -4.72%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.
URL https://www.royaltypharma.com
Investor Relations URL https://www.royaltypharma.com/investors
HQ State/Province New York
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Blend
Next Earnings Release Nov. 10, 2022 (est.)
Last Earnings Release Aug. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Aug. 18, 2022

Dividends

Dividend Per Share (TTM) 0.72
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 1.346
Yield to Sector 1.036
Yield to Industry 2.665
Last Dividend Amt. 0.19
Dividend Frequency Quarterly
Last Ex-Dividend Date Aug. 18, 2022
Yield (TTM) 1.83%
Forward Yield 1.88%
Payout Ratio 66.92%
Cash Payout Ratio 15.64%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
--
--
--
--
--
-19.07%
2.61%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-21.61%
--
6.49%
168.8%
-28.51%
48.60%
40.00%
-4.49%
-38.78%
41.48%
-84.98%
-1.59%
48.39%
-89.18%
2.70K%
28.30%
-85.32%
-22.11%
1.52%
32.62%
22.97%
-18.85%
-12.50%
39.23%
-31.59%
9.85%
94.51%
-12.52%
-8.25%
1.17%
-31.36%
-37.82%
-9.59%
As of September 23, 2022.

Profile

Edit
Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.
URL https://www.royaltypharma.com
Investor Relations URL https://www.royaltypharma.com/investors
HQ State/Province New York
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Blend
Next Earnings Release Nov. 10, 2022 (est.)
Last Earnings Release Aug. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Aug. 18, 2022

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
MGHRX 411.48M USD 6.68%
MBIRX 125.10M USD 6.28%
TAAEX 112.13M USD 6.11%
IHE 17.79M USD 4.45%
IPO 5.744M USD 3.63%
XPH 7.184M USD 3.38%
FACTX 139.73M USD 2.38%
FSPHX 203.05M USD 2.37%
QQQN 1.941M USD 2.04%
ZUH.TO 6.739M USD 1.60%
QQQJ 11.75M USD 1.59%
VHGEX 89.09M USD 1.27%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter RPRX Tweets